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Background: Early dual antiplatelet therapy (DAPT) improves outcomes in patients with MI. Its use in MI patients after the introduction of 
prasugrel into practice has not been studied.
Methods: Using ACTION Registry-GWTG, we evaluated thienopyridine use within 24 hours of admission in 43134 STEMI and 67086 NSTEMI patients 
from 10/1/09 - 3/31/11, excluding patients with contraindications or who transferred out or died within 24 hours.
Results: A substantial proportion of NSTEMI patients (42%) were not treated with early thienopyridines despite their high-risk profile(Table). 
Prasugrel use increased considerably from Q4 2009 (3.0%; 5% STEMI, 1.6% NSTEMI) to Q1 2011 (12%; 20% STEMI, 6.3% NSTEMI). STEMI patients 
were more likely to receive early prasugrel than NSTEMI patients (p<0.001). Using ACTION derived risk scores, prasugrel-treated patients had 
significantly lower predicted risks of both bleeding and mortality than clopidogrel-treated patients. Prasugrel-treated patients were more likely to 
undergo early PCI, and prasugrel was often initiated after catheterization. Although contraindicated, 1.8% of prasugrel-treated patients had prior 
stroke. Also, 2.8% of prasugrel-treated patients were low weight (<60kg) and 3.4% were ≥75 years of age (cautionary use per FDA).
Conclusions: Contemporary practice still shows under use of DAPT and paradoxical use of more potent therapy in lower risk patients. These data 
should inform physicians on the choice to increase utilization of new antiplatelet agents. 
NSTEMI STEMI
No drug
N=28436 (42%)
Clopidogrel
N=35566 (53%)
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P 
No drug
N=4211 (10%)
Clopidogrel
N=32933 (76%)
Prasugrel
N=5990 (14%)
P 
Age (years)* 70 (59;80) 65 (55;76) 57 (49;63) <0.0001 66 (56;77) 61 (52;71) 56 (49;63) <0.0001
Male (%) 58% 63% 76% <0.0001 62% 70% 78% <0.0001
DM (%) 38% 36% 28% <0.0001 30% 23% 22% <0.0001
Prior MI (%) 26% 32% 21% <0.0001 20% 19% 19% 0.04
Prior Thienopyridine (%) 8% 29% 14% <0.0001 8% 9% 10% <0.0001
ACTION predicted mortality risk 
score*
30 (24;38) 28 (22;35) 23 (19;28) <0.0001 36 (29;45) 32 (27;38) 30 (25;34) <0.0001
ACTION predicted bleeding risk 
score*
28 (22;34) 25 (20;31) 20 (17;24) <0.0001 32 (27;40) 28 (24;34) 26 (23;30) <0.0001
In-hospital PCI (NSTEMI) or Primary 
PCI (STEMI) (%)
31% 61% 94% <0.0001 54% 88% 93% <0.0001
Drug initiation prior to 
catheterization (%)
- 64% 16% - - 47% 13% -
*continuous variables presented as medians with 25th and 75th percentiles
